Inclusion Criteria:  Cytologically or histologically proven Nasopharyngeal Carcinoma(WHO 2003 I-III) . Presence of at least one measurable target lesion (RECIST rules) in a non irradiated region; age ≥18 years; radiation therapy history for histologically confirmed NPC administered≥6 months prior to study entry; radiographic evidence to support the diagnosis of RN with out tumor recurrence or metastases; patients had never received Antiangiogenic agents for RN treatment prior to the screening; patients had never received corticosteroids for RN treatment prior to the screening; no evidence of very high intracranial pressure suggestive of a brain hernia requiring surgery routine laboratory studies including urinalysis, complete blood count, liver function, renal function, and coagulation test within a normal range; to understand and be willing to sign a written informed consent.  Exclusion Criteria:  Other types of Nasopharyngeal Carcinoma; Recurrent nasopharyngeal carcinoma, resection of encephalopathy, metastasis, hepatitis, other malignant tumors, neurovascular diseases, or other diseases of the nervous system; Inadequately controlled diabetes (FBG > 10mmol/L) and hypertension(systolic blood pressure > 140 mmHg, diastolic blood pressure > 90 mmHg); Other severe concurrent disorders that occurred before enrollment (severe or unstable angor, NYHA class 3 or 4 congestive heart failure, Myocardial infarction occurred within 6 months before enrollment；Aortic dissection aortic aneurysm.) active central nervous system hemorrhage; pregnant or lactating women, women who have not undergone a pregnancy test (within 14 days prior to initial administration), and pregnant women; Patients with a history of severe mental illness or communication disorders.